芬氟拉明治疗接受司替戊醇方案的Dravet综合征耐药发作
这项多中心双盲安慰剂对照随机临床试验纳入87例2-18岁Dravet综合征患儿,其司替戊醇方案控制不佳。芬氟拉明0.4 mg/kg/d较安慰剂显著降低每月惊厥发作频率54.0%,54%患者发作减少≥50%,无心脏瓣膜病或肺动脉高压证据。
要点
- 芬氟拉明0.4 mg/kg/d较安慰剂额外减少54.0%月惊厥发作频率。
- 54%芬氟拉明组患者月惊厥发作减少≥50%,安慰剂组仅5%。
- 常见不良事件为食欲下降、疲劳、腹泻和发热,无心脏毒性证据。
核心结论
- 在司替戊醇方案控制不佳的Dravet综合征患者中,芬氟拉明显著改善每月惊厥发作频率且总体耐受良好,可能成为新的治疗选择。
研究设计与样本
- 多中心双盲安慰剂对照平行组随机临床试验,纳入87例2-18岁确诊Dravet综合征且接受稳定司替戊醇方案、基线6周内≥6次惊厥发作的患儿。
- 患者随机接受芬氟拉明0.4 mg/kg/d(最大17 mg/d,n=43)或安慰剂(n=44),滴定3周后维持12周,主要终点为联合滴定与维持期相对基线的月惊厥发作频率变化。
主要发现
- 芬氟拉明组较安慰剂组月惊厥发作频率额外降低54.0%(95% CI 35.6%-67.2%;P < .001)。
- 芬氟拉明组54%患者月惊厥发作频率减少≥50%,安慰剂组为5%(P < .001)。
- 中位最长无发作间隔芬氟拉明组22天(范围3.0-105.0),安慰剂组13天(范围1.0-40.0)(P = .004)。
- 常见不良事件为食欲下降(芬氟拉明44% vs 安慰剂11%)、疲劳(26% vs 5%)、腹泻(23% vs 7%)和发热(26% vs 9%)。
- 心脏监测未发现瓣膜性心脏病或肺动脉高压的临床或超声心动图证据。
临床怎么用
- 对于司替戊醇方案控制不佳的Dravet综合征患儿,可考虑加用芬氟拉明0.4 mg/kg/d(最大17 mg/d)以减少惊厥发作频率。
- 治疗期间应监测食欲下降、疲劳、腹泻和发热等不良事件,并进行心脏监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Fenfluramine treatment may reduce monthly convulsive seizure frequency in patients with Dravet syndrome who have poor seizure control with their current stiripentol-containing antiepileptic drug regimens. OBJECTIVE: To determine whether fenfluramine reduced monthly convulsive seizure frequency relative to placebo in patients with Dravet syndrome who were taking stiripentol-inclusive regimens. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, parallel-group randomized clinical trial was conducted in multiple centers. Eligible patients were children aged 2 to 18 years with a confirmed clinical diagnosis of Dravet syndrome who were receiving stable, stiripentol-inclusive antiepileptic drug regimens. INTERVENTIONS: Patients with 6 or more convulsive seizures during the 6-week baseline period were randomly assigned to receive fenfluramine, 0.4 mg/kg/d (maximum, 17 mg/d), or a placebo. After titration (3 weeks), patients' assigned dosages were maintained for 12 additional weeks. Caregivers recorded seizures via a daily electronic diary. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the change in mean monthly convulsive seizure frequency between fenfluramine and placebo during the combined titration and maintenance periods relative to baseline. RESULTS: A total of 115 eligible patients were identified; of these, 87 patients (mean [SD], age 9.1 [4.8] years; 50 male patients [57%]; mean baseline frequency of seizures, approximately 25 convulsive seizures per month) were enrolled and randomized to fenfluramine, 0.4 mg/kg/d (n = 43) or placebo (n = 44). Patients treated with fenfluramine achieved a 54.0% (95% CI, 35.6%-67.2%; P < .001) greater reduction in mean monthly convulsive seizure frequency than those receiving the placebo. With fenfluramine, 54% of patients demonstrated a clinically meaningful (≥50%) reduction in monthly convulsive seizure frequency vs 5% with placebo (P < .001). The median (range) longest seizure-free interval was 22 (3.0-105.0) days with fenfluramine and 13 (1.0-40.0) days with placebo (P = .004). The most common adverse events were decreased appetite (19 patients taking fenfluramine [44%] vs 5 taking placebo [11%]), fatigue (11 [26%] vs 2 [5%]), diarrhea (10 [23%] vs 3 [7%]), and pyrexia (11 [26%] vs 4 [9%]). Cardiac monitoring demonstrated no clinical or echocardiographic evidence of valvular heart disease or pulmonary arterial hypertension. CONCLUSIONS AND RELEVANCE: Fenfluramine demonstrated significant improvements in monthly convulsive seizure frequency in patients with Dravet syndrome whose conditions were insufficiently controlled with stiripentol-inclusive antiepileptic drug regimens. Fenfluramine was generally well tolerated. Fenfluramine may represent a new treatment option for Dravet syndrome. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02926898.
引用
- Nabbout R, Mistry A, Zuberi S, et al. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial. JAMA Neurol. 2020. PMID: 31790543. doi:10.1001/jamaneurol.2019.4113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。